[Click eStock] "The Foundation of Domestic CDMO Growth, Top 3 Bio SoBuJang"

ResearchAlum analyzed on the 26th that the global pharmaceutical supply chain is being reorganized as conflicts between the United States and China intensify. It predicted that domestic Contract Development and Manufacturing Organization (CDMO) companies will benefit.

Choi Seonghwan, a researcher at ResearchAlum, explained, "The United States' Biosecure Act is scheduled for a House vote this September," adding, "It aims to strengthen the protection of technology and biological resources." He continued, "It strictly limits the overseas transfer of bio technology," and "Global pharmaceutical companies in the US and Europe are paying attention to domestic CDMO companies like Samsung Biologics, which possess technical capabilities and production capacity."

He analyzed, "The rapid growth of the CDMO market is providing significant opportunities for bio materials, parts, and equipment companies," and "It is time to focus on companies supplying essential equipment and materials for cell culture technology, which forms the foundation of biopharmaceutical development."

He then introduced, "Amicogen is a company supplying key raw materials for biopharmaceutical production," and "Synergy Innovation possesses microbial culture media technology." He added, "Microdigital produces bioreactors and analytical equipment essential for cell culture."